Raquel E. Izumi - Aug 12, 2024 Form 4 Insider Report for Vincerx Pharma, Inc. (VINC)

Role
President and Chief Operations Officer, Director
Signature
By: /s/ Alexander A. Seelenberger, attorney-in-fact
Stock symbol
VINC
Transactions as of
Aug 12, 2024
Transactions value $
$0
Form type
4
Date filed
8/14/2024, 08:00 PM
Previous filing
May 29, 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VINC Stock Option (right to buy) Disposed to Issuer -76.5K -100% 0 Aug 12, 2024 Common Stock 76.5K $6.26 Direct F1, F2
transaction VINC Stock Option (right to buy) Award +76.5K 76.5K Aug 12, 2024 Common Stock 76.5K $0.55 Direct F1, F2
transaction VINC Stock Option (right to buy) Disposed to Issuer -60K -100% 0 Aug 12, 2024 Common Stock 60K $1.71 Direct F1, F3
transaction VINC Stock Option (right to buy) Award +60K 60K Aug 12, 2024 Common Stock 60K $0.55 Direct F1, F3
transaction VINC Stock Option (right to buy) Disposed to Issuer -60K -100% 0 Aug 12, 2024 Common Stock 60K $0.82 Direct F1, F4
transaction VINC Stock Option (right to buy) Award +60K 60K Aug 12, 2024 Common Stock 60K $0.55 Direct F1, F4
transaction VINC Stock Option (right to buy) Disposed to Issuer -90K -100% 0 Aug 12, 2024 Common Stock 90K $1.17 Direct F1, F5
transaction VINC Stock Option (right to buy) Award +90K 90K Aug 12, 2024 Common Stock 90K $0.55 Direct F1, F5
transaction VINC Stock Option (right to buy) Disposed to Issuer -124K -100% 0 Aug 12, 2024 Common Stock 124K $7.38 Direct F1, F6
transaction VINC Stock Option (right to buy) Award +124K 124K Aug 12, 2024 Common Stock 124K $0.55 Direct F1, F6
transaction VINC Stock Option (right to buy) Disposed to Issuer -41.3K -100% 0 Aug 12, 2024 Common Stock 41.3K $7.38 Direct F1, F6
transaction VINC Stock Option (right to buy) Award +41.3K +33.33% 165K Aug 12, 2024 Common Stock 41.3K $0.55 Direct F1, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On August 12, 2024, the stockholders of the Issuer approved the repricing of certain outstanding options to purchase common stock (the "Repriced Options"), with the new exercise price being the closing price of the Issuer's common stock on the Nasdaq Capital Market on August 12, 2024, rounded up to the nearest penny (the "Repricing"). There is no change to the number of shares underlying the Repriced Options or the vesting schedule or expiration dates of the Repriced Options. The Repricing was approved by the Board of Directors of the Issuer on June 26, 2024, based on the recommendation of the Compensation Committee of the Board of Directors.
F2 Option vests over three years, with 1/3 of the shares vesting on December 23, 2022, and 1/36th of the shares vesting monthly thereafter.
F3 Option vests in twenty-four equal monthly installments starting from August 25, 2022.
F4 Option vests in twenty-four equal monthly installments starting from November 15, 2022.
F5 Option vests in twenty-four equal monthly installments starting from February 15, 2023.
F6 One-third (1/3) vests on March 7, 2025, with the remainder vesting in twenty-four equal monthly installments thereafter.

Remarks:

President and Chief Operations Officer